TOKYO (Reuters) - Takeda Pharmaceutical Co <4502.T> said on Wednesday that it would cut about 10 percent of its workforce through job reductions outside Japan as it seeks to streamline its global operations succeeding its acquisition of Swiss drugmaker Nycomed hindmost year.

Japan's largest drugmaker plans to cut 2,100 jobs mainly in Europe and 700 in the United States ~ means of March 2016. As a result, Takeda expects to redeem about 200 billion yen ($2.6 billion) during the same timeframe, it said in a mention.

But Takeda, which employs about 30,000 the masses globally, said the move initially would subside its profit by 35 billion yen in the financial year ending in March. It enjoin announce revised forecasts for the current fiscal year on February 1.

Takeda, that competes against Astellas Pharma <4503.T>, Otsuka Holdings Co <4578.T> and Daiichi Sankyo Co <4568.T> in c~tinuance its home turf, is struggling to boost profits what is ~ to a strong yen and costs related to the Nycomed buyout. Takeda in November cut its full-year operating profit calculate by 31 percent.

Takeda in May agreed to corrupt Nycomed for 9.6 billion euros (or $13.7 billion at the time), to boost its state-room in emerging markets and add a unused lineup of drugs. ($1 = 76.8100 Japanese yen)

(Reporting by Junko Fujita; Editing by Chris Gallagher)

@yahoonews put ~ Twitter, become a fan on Facebook